Roche presents new and updated data for fixed-duration Columvi and Lunsumio at ASH 2024 meeting: Basel Wednesday, December 11, 2024, 11:00 Hrs [IST] Roche announced that new and u ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

While 88.1% of patients completed one cycle, patient adherence beyond the fourth cycle was relatively low.

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

Researchers from City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States, whose Los Angeles comprehensive cancer center is ranked among ...

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH)—a rare, aggressive ...